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The generation of human induced pluripotent stem
cells (iPSCs) holds great promise for the develop-
ment of regenerative medicine therapies to treat a
wide range of human diseases. However, the gener-
ation of iPSCs in the absence of integrative DNA vec-
tors remains problematic. Here, we report a simple,
highly reproducible RNA-based iPSC generation
approach that utilizes a single, synthetic self-repli-
cating VEE-RF RNA replicon that expresses four
reprogramming factors (OCT4, KLF4, and SOX2,
with c-MYC or GLIS1) at consistent high levels prior
to regulated RNA degradation. A single VEE-RF
RNA transfection into newborn or adult human fibro-
blasts resulted in efficient generation of iPSCs with
all the hallmarks of stem cells, including cell surface
markers, global gene expression profiles, and in vivo
pluripotency, to differentiate into all three germ
layers. The VEE-RF RNA-based approach has broad
applicability for the generation of iPSCs for ultimate
use in human stem cell therapies in regenerative
medicine.
INTRODUCTION
The generation of human induced pluripotent stem cells (hiPSCs)
by retroviral expression of four reprogramming factors opened
the potential for regenerative medicine therapies based on
patient-specific, personalized stem cells (Takahashi and Yama-
naka, 2006; Takahashi et al., 2007; Yu et al., 2007). However, the
insertional mutagenic potential of retroviruses combined with
the potential for latent reprogramming factor gene activation,
especially c-MYC, all but eliminates integrative DNA-based
approaches for use in regenerative medicine therapies (Okita
and Yamanaka, 2011; Gonza´lez et al., 2011; Hussein et al.,
2011; Ben-David and Benvenisty, 2011). Several methods based
on DNA, RNA, miRNAs, and proteins have been developed to246 Cell Stem Cell 13, 246–254, August 1, 2013 ª2013 Elsevier Inc.generate integration-free iPSCs, and the advantages and disad-
vantages have been discussed elsewhere (Gonza´lez et al., 2011;
Hussein et al., 2011; Mochiduki and Okita, 2012; Okita and
Yamanaka, 2011). Of all these methods, RNA-based iPSC
approaches using Sendai virus (Fusaki et al., 2009), miRNAs,
and mRNA transfection (Warren et al., 2010) avoid potential inte-
gration problems associated with DNA-based approaches and
at this point in time appear inherently safer methods for future
clinical applications.
Expression of pluripotent factors by infection with Sendai
virus, a negative-sense, single-stranded RNA virus that does
not go through a DNA intermediate, offers a highly efficient iPS
approach in the absence of concerns for integration into the
genome (Fusaki et al., 2009; Ban et al., 2011). However, due to
persistent Sendai virus replication in iPSC clones, this approach
requires a negative selection step followed by one or more
recloning steps from the single-cell level to isolate virus-free
iPSCs. A temperature-sensitive mutant of Sendai virus is a suc-
cessful alternative method to remove the virus (Ban et al., 2011),
though it requires a higher biosafety due to production of infec-
tious virus particles. One of themore-promising non-DNA-based
iPS approaches involves transfection of four individual RF
mRNAs generated by in vitro transcription (Warren et al., 2010,
2012; Angel and Yanik, 2010). Recent work has shown that
activation of the innate immune system enhances the overall
efficiency of iPSC generation by repeated mRNA transfection
(Lee et al., 2012). However, due to the rapid degradation of re-
programming factor mRNAs, this approach requires repetitive
daily transfection of four individual mRNAs into the same target
cells over the 14-day reprogramming period. Although both
Sendai virus and mRNA transfection approaches have been
shown to generate iPSCs, there remains a significant need for
a simple, highly reproducible, non-DNA-based approach to
generate hiPSCs.
To develop an RNA-based iPSC generation strategy, we
focused our efforts on an approach that (1) utilizes a single
RNA species capable of self-replicating for a limited number of
cell divisions, thereby reducing the number of transfections;
(2) is capable of encoding at least four reprogramming factor
open reading frames (ORFs); (3) consistently expresses all re-
programming factor genes at high threshold levels over multiple
Figure 1. Construction and Persistence of
Synthetic VEE-RF RNA Replicons in Primary
Human Fibroblasts
(A) Schematic of VEE-RF RNA replicons. 50 end
nsP1–nsP4, nonstructural proteins 1–4; 30 end C,
E2, and E1, structural proteins. Location of 26S in-
ternal promoter, ribosome-shifting 2A peptide, IRES
sequence, puromycin (Puro)-resistance gene, and
PCR detection of replicon as indicated.
(B) B18R-CM conditioned media and puromycin
selection are required for the persistence of VEE-
GFP RNA over 7 days. HFF cells were transfected on
day 0 with VEE-GFP RNA and treated as indicated.
GFP fluorescence of GFP-positive cell population
was measured by flow cytometry. Error bars repre-
sent the SD of duplicate samples from representa-
tive experiments.
(C) B18R-CM and puromycin are required for reten-
tion of VEE-GFP RNA. Photographs of GFP expres-
sion on day 7 as indicated. Scale bars, 200 mm.
(D) Immunoblot analysis of VEE RNA-expressed
reprogramming factors expressed in HFF cells on
day 1 versus retrovirus (RV-4Fs: OCT4, SOX2, KLF4,
c-MYC) expression.
See also Figure S1.
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degraded in a controlled fashion. To ectopically express all
four reprogramming factors, we modified a noninfectious (non-
packaging), self-replicating Venezuelan equine encephalitis
(VEE) virus RNA replicon (Kinney et al., 1989; Petrakova et al.,
2005) that is currently being investigated as an expression plat-
form for vaccine development (Davis et al., 2002; Durbin and
Whitehead, 2010). The VEE replicon is a positive-sense, single-
stranded RNA that mimics cellular mRNA with a 50 cap and
poly(A) tail and does not utilize a DNA intermediate, so there is
no potential for genomic integration (Kinney et al., 1989). Here,
we report on the generation of hiPSCs by a single transfection
of a self-replicating VEERNAspecies that expresses four reprog-
ramming factor ORFs (OCT4, KLF4, SOX2, with either c-MYC or
GLIS1). VEE-reprogramming factor (VEE-RF) RNA generated
hiPSCs that were free of VEE RNA and had all the hallmarks of
human stem cells (expression of embryonic stem cell [ESC]Cell Stem Cell 13, 246–markers, global gene expression, and
differentiation in vivo into all three germ
lineages). The VEE-RF RNA can also be
selectively retained or removed from cells.
The non-DNA and nonintegrating, self-
replicating VEE RNA approach has the po-
tential to simplify the generation of hiPSCs
for use in disease cell-modeling studies
and eventual cell therapy applications.
RESULTS
Development of Self-Replicative VEE
RNA to Express Reprogramming
Factors
To develop a single RNA iPSC generation
approach, we focused on a polycistronic,self-replicative RNA system that would consistently express
the reprogramming factors over multiple cellular divisions. We
modified a noninfectious, self-replicating VEE RNA (Petrakova
et al., 2005). VEE RNA is a positive-stranded RNA that encodes
four nonstructural replication complex proteins (nsPs) as a single
ORF in the 50 end of the RNA that is separated from the viral
structural protein ORFs in the 30 end (Figure 1A). Petrakova
et al. showed the ability to express exogenous proteins by re-
placing the 30 structural protein ORFs with GFP (Petrakova
et al., 2005). To evaluate the VEE RNA replicon in primary human
fibroblasts, we replaced the 30 ORF with GFP, followed by an in-
ternal ribosomal entry site (IRES) (Pelletier and Sonenberg, 1988)
and a Puromycin-resistance gene (Puror) (Figure 1A). Current
SP6 or T7 RNA in vitro transcription kits can transcribe RNAs
in excess of 25 kb in length (Schelle and Thiel, 2007). VEE-GFP
RNA was produced using either SP6 or T7 RNA polymerases
from a standard in vitro transcription kit followed by 50 capping,254, August 1, 2013 ª2013 Elsevier Inc. 247
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11,500 nt RNA transcript. In our hands, both SP6 and T7 RNA
polymerases readily produced high-yield in vitro transcripts in
excess of 14,000 nt (Figure S1A available online).
Exposure of cells to single-stranded VEE RNA induces a
strong interferon (IFN)-a/b innate immune response. To mitigate
the innate immune response to VEE-GFP RNA, we utilized B18R
protein fromWestern vaccinia virus that binds to and neutralizes
type I IFNs (Alcamı´ et al., 2000).We compared GFP expression in
primary human foreskin fibroblasts (HFFs) transfected with VEE-
GFP RNA alone or cotransfected with B18R mRNA. Consistent
with induction of a strong innate immune response to cells
exposed to single-stranded RNA, in the absence of B18R, we
observed little-to-no GFP expression 1 day after transfection
(Figure S1B). In contrast, cotransfection of VEE-GFP RNA repli-
conwith B18RmRNA resulted in high levels of GFP expression in
HFFs (Figure S1B), showing that B18R is required for efficient
expression of proteins from the VEE RNA replicon.
The generation of iPSCs requires consistent, high-level ex-
pression of reprogramming factors for >7 days; therefore, we
examined the persistence of the VEE-GFP RNA replicon in
human primary fibroblasts over 7 days. To continuously sup-
press the innate immune response over several weeks while
avoiding daily transfection of B18R mRNA, we prepared condi-
tioned media harvested from human fibroblasts expressing
B18R protein (B18R-CM) (Figures S1C and S1D). HFFs were
cotransfected with VEE-GFP RNA replicon and B18R mRNA
(3:1 ratio) on day 0, then cultured in the presence or absence
of 20% B18R-CM plus/minus puromycin on day 1 (Figure 1B).
Puromycin selection in the presence of B18R-CM resulted in
a >90% GFP-positive population, whereas puromycin selection
in the absence of B18R-CM resulted in <1% viable GFP cells
(Figures 1B and 1C). We also observed that the level of GFP
expression in the presence of B18R-CM gradually decreased
from day 1 to day 4 but then remained steady out to day 7. In
contrast, the level of GFP expression in the absence of B18R-
CM continuously dropped to <10% intensity (Figure 1B). VEE
GFP replicon persistence was dose dependent on B18R-CM
(Figures S1E and S1F). We note the persistence of high levels
of GFP expression from VEE-GFP RNA-treated fibroblasts for
over a month when continuously cultured in the presence of
B18R-CM and puromycin (data not shown). Taken together,
these results showed both the necessity of B18R protein to over-
come the VEE RNA-induced innate immune response and also
demonstrated the ability to selectively retain or degrade the
VEE RNA replicon from cells by exposure to or withdrawal
from B18R-CM.
Generation of iPSCs by VEE RNA Replicon
We next engineered the VEE RNA replicon 30 ORF to encode four
reprogramming factors (OCT4, KLF4, SOX2, with c-MYC or
GLIS1), which avoids the potential genomic instability induced
by c-MYC (Nakagawa et al., 2008; Maekawa et al., 2011). We
generated and compared several VEE-RNA construct configura-
tions (Figure 1A) using the following nomenclature: VEE-OMKS =
OCT4, c-MYC, KLF4, SOX2 separated by internal ribosomal
skipping 2A peptides (Szymczak et al., 2004) followed by an
IRES and Puror ORF; VEE-OKS-iM = OCT4, KLF4, SOX2 sepa-
rated by 2A peptides followed by an IRES then c-MYC and a248 Cell Stem Cell 13, 246–254, August 1, 2013 ª2013 Elsevier Inc.second IRES and Puror ORF; and VEE-OKS-iG = OCT4, KLF4,
SOX2 separated by 2A peptides followed by IRES then GLIS1
and a second IRES and Puror ORF (Figure 1A). Similar to the
VEE-GFP RNA protocol, VEE-RF RNAs were produced by SP6
or T7 in vitro transcription, 50 capping, and poly(A) tail addition re-
sulting in full-length VEE-OKS-iM RNA, VEE-OMKS RNA, and
VEE-OKS-iG RNA (Figure S1A). Transfection of various VEE-RF
RNA replicons with B18R mRNA into human fibroblasts resulted
in high levels of expression of all four reprogramming factors that
exceeded reprogramming factor expression levels from retrovi-
ruses on day 1 and day 10 (Figures 1D and S2B). Together, these
observations demonstrated the ability to express four reprog-
ramming factors and a Puror gene from a single, synthetic
VEE-RF RNA replicon in primary human cells, while utilizing
B18R to block the innate immune response.
To develop a VEE-RF RNA replicon-based iPSC protocol, we
evaluated several parameters, including number and timing of
VEE-RF RNA transfections, selection for VEE-RF RNA replicon
retention by puromycin, and the genetic organization of the
VEE-RF RNA replicon (Figures 1A, 2A, and S2). Human HFFs
or BJ fibroblasts were cotransfected with VEE-RF RNA replicons
and B18R mRNA on day 1, then cultured in the presence of 20%
B18R-CM plus puromycin. Based on expression results of VEE-
RF RNAs (Figures 1D and S2), we initially compared iPSC gener-
ation from either twice (days 1 and 3) or five-times (days 1, 3, 5, 7,
and 9) transfections of VEE-OMKS RNA or VEE-OSK-iM RNA.
Strikingly, alkaline phosphatase (AP)-positive staining iPS col-
onies were only generated from VEE-OKS-iM RNA in both BJ
and HFFs, and no iPSC colonies were observed from VEE-
OMKS RNA (Figure 2B). One significant difference between the
two RNA vectors is the relative level of c-MYC expression to
the other reprogramming factors with lower c-MYC levels ex-
pressed from the VEE-OKS-iM RNA, where c-MYC is the last
ORF with a 50 IRES, and higher levels of c-MYC expressed
from the VEE-OMKS RNA non-iPS-generating replicon, where
c-MYC is the second ORF and utilizes a 2A ribosome-skipping
peptide (Figures 1A, 1D, and S2B). Moreover, we noted an in-
verse c-MYC expression sensitivity to generating iPSCs using
retroviral vectors, where high c-MYC levels were correlated
with a decreased number of iPSC colonies. Using VEE-OKS-iM
RNA, we further optimized conditions for iPSC generation and
found that B18R-CM was required until the appearance of
iPSC colonies on feeding culture, whereas puromycin could be
removed at the point of plating onto feeder cultures (Figure S2C).
To avoid the potential for genomic instability induced by
c-MYC, we also generated a related VEE-OKS-iG RNA construct
that substituted GLIS1 for c-MYC (Figure 1A). Initially, we found
that several transfections of either VEE-OKS-iM RNA or VEE-
OKS-iG RNA in the presence of B18R-CM and puromycin selec-
tion over the first 7 days resulted in the highest generation of
AP-positive colonies (Figures 2C and 2D; Table S1). Starting
with one well of a 6-well format (43 105 cells/well), we generally
observed >100 iPS colonies per starting well from both HFFs
and BJ fibroblasts when using three (or more) VEE-RF RNA
transfections (Table S1). Although iPSCs were generated in the
absence of puromycin selection, we observed a substantially
reduced efficiency. To further refine the approach, we changed
the type of media used during the first 7 days after transfection
to either Advanced-DME or Pluriton, both of which resulted in
Figure 2. Generation of iPSCs by VEE-
RF RNA
(A) Schematic of epigenetic VEE-RF RNA iPSC
generation protocol. Human fibroblasts were
plated on day 0 and cotransfected (Tfx) with VEE-
RF RNA replicon plus B18R mRNA on day 1
(confluent, 4 3 105 cells) and treated with puro-
mycin until day 7 (or 10) as indicated. Cells were
cultured in B18R-CM until iPSC colonies were
isolated on day 25 (to 30).
(B) iPSC colonies stained with AP were generated
with VEE-OKS-iM RNA, but not VEE-OMKS RNA.
Transfection was performed on days 1 and 3
(23 Tfx), or 1, 3, 5, 7 and 9 (53 Tfx).
(C) AP staining of iPSC colonies generated from
BJ or HFFs from day 1, 4, 7, and 10 transfection
protocol as indicated.
(D) Typical images of iPSC colonies on day 26 by
VEE-OKS-iM RNA and day 22 for VEE-OKS-iG
RNA from BJ or HFFs fibroblasts as indicated.
Scale bars, 100 mm.
(E) Immunohistochemistry staining of pluripotent
ESmarker genes in isolated iPSC clones generated
as indicated. Similar results obtained for 26 addi-
tional iPSC clones (30 clones total). Scale bar,
100 mm; insets, 103 amplification.
See also Figures S2, S3, and S4.
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of either VEE-OKS-iM RNA or VEE-OKS-iG RNA in BJ or HFFs
(Table 1). Moreover, a single transfection of VEE-OKS-iM RNA
or VEE-OKS-iG RNA produced from either SP6 or T7 RNA poly-
merases into human adult cells of normal human dermal fibro-
blasts (NHDF-c) (aged 50) and human dermal fibroblasts
(HDFs) (aged 58) generated AP-positive colonies with a charac-
teristic iPSCmorphology (Table 1). Thus, we refined themethod-
ology to generate iPSCs from a single transfection of the VEE-RF
RNA replicon into both newborn and adult human fibroblasts.
Characterization of iPSC Clones
We mechanically isolated >100 iPSC colonies from multiple in-
dependent VEE-OKS-iM RNA and VEE-OKS-iG RNA protocols
and had a >95% success rate for the ability of isolated iPS
clones to continuously divide and retain a human embryonic
stem cell (hESC) morphology. Of the >100 iPS morphology-
like clones isolated, we analyzed 30 clones for expression of
stem cell markers by immunofluorescence. All 30 VEE-RF
RNA iPS clones analyzed (63 HFF VEE-OKS-iM clones, 123
BJ VEE-OKS-iM clones, 63 HFF VEE-OKS-iG clones, 63 BJ
VEE-OKS-iG clones) showed strong nuclear staining of endog-
enous OCT4, SOX2, and NANOG and strong cell surface stain-
ing of SSEA4, TRA-1-60, and TRA-1-81, with negative stainingCell Stem Cell 13, 246–2of SSEA1 (Figure 2E). In addition, we
examined six clones from HDF human
adult fibroblasts and three clones from
NHDF-c human adult fibroblasts by
immunofluorescence and found that all
clones expressed TRA-1-60, TRA-1-81,
SSEA4, and NANOG but did not express
SSEA1 (Figures S3 and S4).Continuous exposure to B18R-CM was essential for both
retention of the VEE-RF RNA replicon and iPSC generation (Fig-
ures 1B and S2C). Withdrawal of B18R-CM from iPS culture
medium resulted in the elimination of the VEE-RF RNA replicon.
To confirm the complete loss of VEE-RF-RNA replicons, we
developed a highly sensitive and specific PCR protocol capable
of detecting <10 fg of the VEE-RF-RNA replicon (Figure S5A).
RT-PCR analysis of isolated RNAs showed that all iPSC clones
had lost the VEE-RF-RNA replicon by passage 8, whereas
most clones lost the RNA replicon in passage 5 or 6 (Figure 3;
Table S2). Geuking et al. (2009) reported that nonretroviral
RNA viruses under extreme conditions can recombine with
endogenous retrotransposon genetic elements and result in a
reverse transcription into DNA followed by genomic integration.
Therefore, we examined VEE-RF iPSC clones for the presence of
DNA copies. However, consistent with an RNA-only vector that
does not go through a DNA intermediate, we did not detect
any genomic integrations of VEE-RF by genomic PCR analysis
or by Southern blot analysis (Figures S5B–S5E). A consistent
concern for iPS generation protocols is the generation of aneu-
ploid or tetraploid iPSC clones (Yu et al., 2007). By flow cytom-
etry DNA analysis, we observed several tetraploid iPSC clones
generated from VEE-RF OKS-iM RNA, but no tetraploid colonies
were detected from VEE-RF OKS-iG RNA (data not shown).54, August 1, 2013 ª2013 Elsevier Inc. 249
Table 1. Generation of iPSCs by Single Transfection of VEE-RF
RNA Replicon






SP6-OKS-iM BJ newborn 1 Pluriton 89
T7-OKS-iM BJ newborn 1 Pluriton 181
SP6-OKS-iM BJ newborn 1 Ad-DME 16
T7-OKS-iM BJ newborn 1 Ad-DME 54
SP6-OKS-iG BJ newborn 1 Pluriton 173
T7-OKS-iG BJ newborn 1 Pluriton 167
SP6-OKS-iG BJ newborn 1 Ad-DME 60
T7-OKS-iG BJ newborn 1 Ad-DME 55
SP6-OKS-iM HFF newborn 1 Pluriton 245
T7-OKS-iM HFF newborn 1 Pluriton 169
SP6-OKS-iM HFF newborn 1 Ad-DME 757
T7-OKS-iM HFF newborn 1 Ad-DME 422
T7-OKS-iG HFF newborn 1 Ad-DME 51
SP6-OKS-iM NHDF-c adult 1 Ad-DME 59
T7-OKS-iM NHDF-c adult 1 Ad-DME 5
SP6-OKS-iG NHDF-c adult 1 Ad-DME 31
T7-OKS-iG NHDF-c adult 1 Ad-DME 44
SP6-OKS-iM HDF adult 1 Ad-DME 8
T7-OKS-iM HDF adult 1 Ad-DME 4
Retroviruses
O, K, S, M
BJ newborn – Ad-DME 117
Retroviruses
O, K, S, M
HFF newborn – Ad-DME 294
Retroviruses
O, K, S, M
NHDF-c adult – Ad-DME 22
VEE-RF RNAs were generated with SP6 or T7 RNA polymerase as indi-
cated. HFFs (male, newborn) or BJ (male, newborn) newborn fibroblasts
or NHDF-c (female, age 50) or HDF (female, age 58) adult fibroblasts were
cotransfected once with VEE-RF RNA replicon and B18R mRNA on
day 1. Cells were selected with puromycin from days 2 to 10. Pluriton
medium was present on days 1–10, and Advanced-DME (Ad-DME) was
present on days 1–7, then changed to ES medium. All cultures were
passaged to STO feeder cells and cultured in ESmedium on day 10. Cells
received daily 20% B18R-CM conditioned medium. iPSC colonies were
stained with AP on day 24, and the number of colonies is indicated based
on the starting well.
See also Table S1.
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generated from both OKS-iM and OKS-iG VEE-RF RNA repli-
cons that showed normal DNA content by flow cytometry con-
tained normal diploid karyotypes (Figure S6).
To further characterize the established iPSC clones, we exam-
ined expression of hES marker genes by qRT-PCR. Consistent
with expression levels in human HUES9 ESCs, iPSC clones
generated from both parental BJ and HFFs with either the
VEE-OKS-iM RNA or VEE-OKS-iG RNA protocol expressed
robust levels of endogenous OCT4, SOX2, NANOG, LIN28,
TDGF1, DNMT3B, and TERT, in contrast to low or no expression
levels in starting parental BJ and HFFs (Figure 4A). Likewise,
VEE-OKS-iM RNA or VEE-OKS-iG RNA-generated iPS clones
from human adult HDFs and NHDF-c fibroblasts also expressed250 Cell Stem Cell 13, 246–254, August 1, 2013 ª2013 Elsevier Inc.OCT4, SOX2, NANOG, LIN28, TDGF1, DNMT3B, and TERT by
qRT-PCR (Figures S3 and S4). A hallmark of induced pluripo-
tency is reduced DNA methylation of CpG dinucleotides in the
OCT4 and NANOG promoter regions (Gonza´lez et al., 2011).
Bisulfite genomic sequencing of both the OCT4 and NANOG
promoter regions showed extensive demethylation in iPSC
clones compared to parental fibroblasts (Figure 4B). To investi-
gate mRNA expression profiles in iPSC clones, we performed
whole-genome RNA sequencing (RNA-seq). All four iPSC clones
analyzed by RNA-seq showed unsupervised hierarchical clus-
tering and expression signatures characteristic of human
HUES9 ESCs that were highly divergent from parental human fi-
broblasts (Figures 4C and 4D). Together, these results demon-
strate that VEE-RF RNA replicon-generated iPSCs have all of
the expression profile hallmarks of hESCs.
Differentiation of VEE-RNA Replicon-Generated iPSC
Clones
Finally, we tested the pluripotency of VEE-RF RNA replicon-
generated hiPSC clones to differentiate in vitro and in vivo. First,
we differentiated iPSCs in vitro into cardiomyocytes per the
method of Yang et al. (2008). Four independent iPSC clones
derived from either the OKS-iM or OKS-iG VEE-RF replicons
(HFF OKS-iM #1, BJ OKS-iM #2 and #21, BJ OKS-iG #5) were
treated with activin A, bone morphogenetic protein 4 (BMP4),
basic fibroblast growth factor (bFGF), vascular endothelial
growth factor (VEGF), and dickkopf homolog 1 (DKK1) in
serum-free media. Differentiated embryoid bodies (EBs) from all
four iPS clones began spontaneously contracting at day 7 and
were stably contracting on day 15 (Movie S1). Using antibodies
against cTNT and a-actinin (Figure 5A), immunohistochemistry
revealed that all four differentiated iPS EBs were positive for
cardiomyocyte markers. These data combined with the sponta-
neously contracting EBs confirm the ability of VEE-RNA repli-
con-generated iPSC clones to differentiate into cardiomyocytes.
To test for in vivo pluripotency to differentiate into cells of all
three germ layers, human VEE-RF RNA iPSC clones were
injected into immunodeficient mice to generate differentiated
teratomas. H&E of sections from two independent iPSC clones
contained representative cell types of all three germ layers (ecto-
derm, endoderm, andmesoderm) that are spread throughout the
sections (Figure 5B). Immunohistochemistry staining of four
additional, independent iPSC-derived teratomas was positive
for ectoderm markers AE1/AE3 (cytokeratin), NF-1 (neuronal
cells), and GFAP (neuronal cells), mesoderm marker Desmin
(muscle cells), and endoderm marker AFP (primitive and defini-
tive endoderm) (Figure 5C). Collectively, these observations
confirm the ability of both VEE-OKS-iM and VEE-OKS-iG RNA
replicons to efficiently generate pluripotent hiPSCs.
DISCUSSION
The generation of iPSCs has great potential for the development
of personalized stem cell therapies (Okita and Yamanaka, 2011;
Gonza´lez et al., 2011; Hussein et al., 2011). Here, we devised a
simple, straightforward and highly reproducible RNA-based
approach to generate hiPSCs by a single transfection of a
synthetic, polycistronic self-replicating VEE-RF RNA replicon
that expresses four independent reprogramming factors plus
Figure 3. RT-PCR Analysis for Persistent
VEE-RF RNA Replicon in iPSC Clones
(A and B) RT-PCR of HFF-OKS-iM iPSC clones
from total RNA prepared from passage 4 (A) and
passage 8 (B), as indicated. +, positive control,
total RNA was prepared from 1 day after trans-
fection of OKS-iM-RNA replicon. , negative
control, total RNA was prepared from mock-
transfected HFFs.
See also Table S2.
Cell Stem Cell
Generation of iPSCs by RNA Replicona selectable marker (Puror) for positive selection of the RNA re-
plicon. We found that both VEE-OKS-iM RNA and VEE-OKS-iG
RNA replicons efficiently and consistently generated iPSCs
from newborn and adult human fibroblasts that acquired full plu-
ripotency by rigorous in vivo biological and molecular criterion
that paralleled hESCs. By expressing four reprogramming fac-
tors at consistent levels and ratios over time in the same cell
combined with replication of the VEE-RF RNA for a limited
number of multiple cell generations, the VEE-RF RNA approach
solves both of the major inefficiency problems associated with
generating iPSCs by repetitive daily transfections of four individ-
ual RF mRNAs.
Consistently maintaining the ratio of reprogramming factors to
each other appears to be critically important for efficiently gener-
ating iPSCs. As an example, we note that expression of toomuch
c-MYC relative to the other factors by the VEE-OMKS RNA repli-
con dramatically inhibited iPSC generation, whereas the lower
c-MYC ratio expressing VEE-OKS-iM RNA replicon was highly
efficient at generating iPSCs. In contrast to simultaneously trans-
fectingmultiplemRNAs for each factor into cells, having the fixed
factor ratio built into the single VEE-RF replicon RNA consistently
results in the appropriate reprogramming factor expression
levels and ratios. The generation of the VEE-RF-RNA transcript
utilizes a standard SP6 or T7 RNA polymerase in vitro transcrip-
tion kit that does not require special conditions and thereby
further simplifies the approach for broad use. Although previ-
ously restricted to generating limited transcript lengths, current
in vitro RNA transcription kits now exceed 25 kb in length
(Schelle and Thiel, 2007), significantly longer than the 15 kb
length of the VEE-RNA replicons generated here. The ability to
generate very long in vitro transcripts allowed us to generate
VEE-RNA replicons with four pluripotent factor ORFs plus a
puromycin selection gene (five ORFs).
Activation of the innate immune system has recently been re-
ported to enhance iPSC generation (Lee et al., 2012). However,
in our hands, inhibiting the innate immune response by B18R
exposure was critical for increased efficiency of iPSC genera-
tion.We speculate that exposure of VEE-RF RNA-harboring cells
to B18R-CM may sufficiently decrease the innate immune
response to allow for VEE-RF RNA persistence, while retainingCell Stem Cell 13, 246–25a low-level innate immune response to
stimulate iPSC generation. Although we
generated the data presented here by a
fixed protocol of B18RmRNAcotransfec-
tion on day 1 followed by addition of
B18R-conditionedmedia, we note in sub-
sequent studies that addition of B18Rcondition media during the transfection, in lieu of B18R mRNA
cotransfection, followed by daily addition of B18R-CM also suf-
ficed to suppress the innate immune response and generated
iPSCs.
The VEE-RFRNAapproach is an ectopic hit-and-run approach
that does not utilize a DNA intermediate, and therefore, there is
no opportunity for integrative mutation that can occur with
DNA vector-based types of iPSC approaches. Moreover, the
timing of VEE-RF RNA replicon loss by degradation can be regu-
lated by B18R-CM withdrawal from the media. Here, we used a
combination of four reprogramming factors (OCT4, KLF4, and
SOX2, with c-MYC or GLIS1) to reproduce the retrovirus iPSC
generation. However, many factors to enhance reprogramming
or generate safer iPSCs have now been reported to generate
iPSCs (Gonza´lez et al., 2011; Hussein et al., 2011; Ben-David
and Benvenisty, 2011; Mochiduki and Okita, 2012). Therefore,
we note that the VEE-RF RNA approach has the versatility to
be engineered to express alternative reprogramming factor com-
binations and/or insertion of additional reprogramming factor
ORFs into the VEE RNA backbone for refining iPSC generation
from specific cell types or for use in driving transdifferentiation.
In summary, the non-DNA-based, self-replicating VEE-RF RNA
approach has broad applicability for the efficient generation of
hiPSCs for use in disease cell-modeling studies and eventual hu-
man cell therapy-regenerative medicine applications.
EXPERIMENTAL PROCEDURES
Experimental Oversight
All animal experiments were performed with the approval of the Institutional
Animal Care and Use Committee of University of California, San Diego (proto-
col number S01103). Studies using human ESCs and hiPSCs were approved
by the IRB/ESCRO committee at University of California, San Diego (project
number 071552ZF).
Cells
BJ foreskin fibroblasts and STO cell line were obtained from ATCC, primary
HFFs were kindly obtained from M. Haas (UCSD), and HUES-9 hESC line
was from D. Melton (HMS). Adult donor NHDF-c and HDFs were obtained
from PromoCell (c-12302) and Cell Applications (106-05a), respectively.
BJ, HFFs, NHDF-c, HDFs, and STO were cultured in DMEM containing
10% FBS, MEM nonessential amino acids (NEAAs), pyruvate, penicillin, and4, August 1, 2013 ª2013 Elsevier Inc. 251
Figure 4. Characterization of VEE-RF RNA
iPSC Clones
(A) Expression of ES maker genes by qRT-RCR
analysis from indicated BJ and HFF VEE-RF RNA
iPSC clones. Error bars represent the SD of tripli-
cate samples.
(B) DNA methylation analysis of NANOG and
OCT4 promoter regions. Solid circle represents
methylated; open circle is demethylated. Numbers
indicate CpG position relative to transcription
start site.
(C) Genome-wide mRNA sequence profile scat-
terplot analysis of BJ-OKS-iM #2 and BJ-OKS-iG
#5 compared to parental human BJ fibroblasts and
human HUES9 ESCs with pluripotency NANOG,
OCT4, and SOX2 indicated.
(D) Unsupervised hierarchical dendrogram of
genome-wide RNA sequence analysis showing
clustering of four independent iPSC clones with
HUES9 compared to BJ fibroblasts.
See also Figures S3, S4, S6, and Table S1.
Cell Stem Cell
Generation of iPSCs by RNA Repliconstreptomycin. HUES-9 and iPSCs were cultured with ES culture medium in
Knockout D-MEM containing 20% Knockout SR, GlutaMAX, NEAA, 2-mer-
captoethanol, penicillin, streptomycin, and bFGF (10 ng/ml). STO feeder cells
were prepared by mitomycin C treatment (10 mg/ml; Sigma-Aldrich). Matrigel
(BD Biosciences)-coated wells and conditioned medium of STO feeder cells
were used for feeder-free culture.
Plasmid Construction
GFP/Pac genes and partial 30 UTR in p50VEE/S/GFP/Pac (VEE backbone
plasmid; a kind gift from I. Frolov) were deleted with XbaI/MfeI digestion and
then introduced the multiple cloning sites (Table S3): IRES and Puror. This
vector was renamed as pVEE-IRES-Puro. Multicistronic expression of RFs
with viral 2A peptide sequences (Table S3) and IRES was constructed in
pBluescript SK+ vector and then cloned into pVEE-IRES-Puro to generate
VEE-OS, VEE-OMKS, VEE-OKS-iM, VEE-OKS-iG plasmids. To generate
RNA with T7 RNA polymerase, SP6 promoter (ATTTAGGTGACACTATAG)
was replaced to T7 promoter (TAATACGACTCACTATAG) by PCR (Table S3)
using the SacI/BstZ17I fragment of VEE vector as a template (SP6 promoter
is located next to the SacI site). B18R (D01019) was obtained from Addgene
and cloned into pTNT vector (Promega) for mRNA synthesis.
RNA Synthesis
VEE plasmids were linearized with MluI digest and used as templates for RNA
synthesis. The synthesis of RNA replicon was performed with the RiboMAX
Large Scale RNA Production System-SP6 or T7 (Promega) kit. After the DNase
treatment, the synthesized RNA was purified by ammonium acetate precipita-
tion (2.5 M). For the 50 capping of RNA, we used ScriptCap m7G Capping Sys-
tem and ScriptCap 20-O-Methyltransferase (Epicenter, currently available from
CELLSCRIPT) to produce cap 1-capped RNA, which proceeds 100% effi-252 Cell Stem Cell 13, 246–254, August 1, 2013 ª2013 Elsevier Inc.ciency of capping. After the 50 capping of RNA,
RNAwas purified by ammonium acetate precipita-
tion, and then additional poly(A) tail (150 bases)
was added by Poly(A) Polymerase (Epicenter,
currently available from CELLSCRIPT). RNA was
purified, resuspended in the RNA Storage Solution
(Ambion) at 1 mg/ml concentration, and stored at
80C. B18R mRNA was synthesized using the
same replicon RNA protocol except for using
25% modified nucleotides (pseudouridine and
5-methyl-cytidine; TriLink BioTechnologies).
Preparation of B18R Conditioned Medium
B18R-CM (conditioned medium) was generated
by B18R mRNA (1 mg for one well of a 6-well plate)transfection into HFFswith Lipofectamine 2000 (Invitrogen). After 3 hr, medium
was changed to Advanced DMEM containing 15% FCS (ESC qualified; Milli-
pore) or ES culture medium. Medium was collected on the next day, filtrated,
and diluted with fresh culture medium to 20% final concentration.
iPSC Generation by Replicon Transfection
BJ and HFFs were passaged to a 6-well plate on day 0 and cultured to 90%–
100% confluency (43 105 cells/well) on day 1. A total of 1 mg RNAmixture (3:1
ratio VEE RNA to B18RmRNA) was transfected with Lipofectamine 2000. After
3 hr, transfection medium was changed to the Advanced DMEM (Invitrogen)
containing 15% FCS (ESC qualified). ES culture medium was used from
day 7. One day after the final transfection, cells were passaged to STO feeder
with several dilutions. ES medium containing B18R-CM was changed every
day until iPSC colonies were generated. Colonies were mechanically picked
for isolation of clones or subjected to AP staining with the Alkaline Phospha-
tase Detection Kit (Millipore) or manually prepared AP-staining solution con-
taining 1 mg/ml of FastRed TR (Sigma-Aldrich) and 0.4 mg/ml of 1-Naphthyl
phosphate (Sigma-Aldrich) in AP buffer (100 mM Tris, 100 mM NaCl, and
50 mM MgCl2 [pH 9.5]).
Optimization of iPSC Generation with One-Time Transfection of
Replicon
Cells were passaged on a gelatin-coated 6-well plate on day 0 and cultured to
90%–100% confluency on day 1. To minimize the IFN response, cells were
started to treat with 20% B18R-CM 20 min before transfection. A total of
1 mg RNA mixture (3:1 ratio VEE RNA to B18R mRNA for SP6 VEE RNA, or
1:1 ratio for T7 VEE RNA) was transfected with Lipofectamine 2000. After
3 hr, transfection medium was changed to the Advanced DMEM or Pluriton
medium (Stemgent) containing 20% B18R-CM. On day 7, Advanced DMEM
Figure 5. Differentiation Assays of VEE-RF
RNA iPSC Clones
(A) VEE-RF RNA iPS clones were differentiated into
cardiomyocytes as described in the Experimental
Procedures. Contractile EBs were recorded (see
Movie S1) and then dissociated and replated
onto slides for immunofluorescence staining with
mouse anti-Cardiac Troponin or mouse anti-
a-actinin, Anti-Mouse IgG Alexa Fluor 488, and
DAPI. Scale bars, 50 mm.
(B) Teratoma formation of VEE-RF RNA iPS clones
in nude mice. H&E; Scale bars, 100 mm.
(C) Immunohistochemistry staining of VEE-RF RNA
iPSC clone teratomas in nude mice. AE1/AE3
(cytokeratin), NF-1 (neuronal cells), and GFAP
(neuronal cells) were used formarkers of ectoderm,
Desmin (muscle cells) was used for a marker of
mesoderm, and AFP (primitive and definitive
endoderm) was used for a marker of endoderm.
Scale bars, 100 mm.
See also Movie S1 and Table S1.
Cell Stem Cell
Generation of iPSCs by RNA Repliconwas replaced to ES culture medium. Puromycin (0.8 mg/ml) was added from
day 2 to 10. Cells were passaged onto STO feeder cells on day 10 and cultured
in ES culture medium. B18R-CM was supplied every day until iPSC colonies
were generated.
qRT-PCR
Total RNAs from feeder-free culture of iPSC clones, HUES-9, BJ, and HFFs
were isolated with RNeasy mini kit. TaqMan RT-PCRs were carried out
using RNA-to-Ct one-step reaction (Applied Biosystems). Primers and probes
were obtained from AB TaqMan Gene Expression Assay catalog (GAPDH,
Hs99999905_m1; POU5F1 Hs03005111_g1; Sox2 Hs01053049_s1; DNMT3B
Hs00171876_m1; TERT Hs00972656_m1; Lin28 Hs00702808_s1; Nanog
Hs02387400_g1; TDGF1 Hs02339499_g1). Data were analyzed on the 7300
real-time PCR system using the delta-delta Ct method.
Bisulfite Genomic Sequencing
Conversion of unmethylated cytosines into uracil of genomic DNA was
performed with EZ DNA Methylation-Gold Kit (Zymo Research). The promoter
region of OCT4 or NANOG was amplified by PCR (Table S3), cloned into the
T vector, and then sequenced.
Immunoblotting
Cells were lysed with 2 3 RIPA buffer containing 0.3 M NaCl, 80 mM Tris-HCl
(pH7.5), 0.4% SDS, 2% Triton X-100, 2% sodium deoxycholate, 100 mg/mlCell Stem Cell 13, 246–2phenylmethanesulfonylfluoride (PMSF), aprotinin
(5 mg/ml), and leupeptin (5 mg/ml). Equal amounts
of proteins (around 20 mg) were used for 9%
SDS-PAGE and electroblotted onto a nitrocellu-
lose membrane. Membranes were incubated with
primary antibodies overnight at 4C after blocking
with 4% milk in PBS-T (0.05% Tween 20) and
then incubated with horseradish peroxidase-con-
jugated anti-rabbit, goat, or mouse IgG (Santa
Cruz Biotechnology). Protein bands were visual-
ized using the ECL reagent (SuperSignal West
Pico; Thermo Scientific).
Antibodies
Antibodies used in this research are as follows:
anti-OCT4 (sc-9081), anti-KLF4 (sc-20691), anti-
GLIS1 (sc-67584), anti-c-MYC (sc-42), TRA-1-60
(sc-21705), SSEA1 (sc-21702), SSEA4 (sc-
21704), anti-mouse (sc-2005), anti-rabbit (sc-
2004), and anti-goat (sc-2020) from Santa Cruz;anti-SOX2 (AF2018) and anti-NANOG (AF1997) from R&D Systems; TRA-
1-81 (09-0011) from Stemgent; AE1/AE3 (RB-9010P0), Desmin (MS-376-
S0), AFP (RB-365), and GFAP (RB-087) from LabVision; NF-1 (NB-300-155)
from Novus Biologicals; anti-a-actinin (A7811) from Sigma-Aldrich; anti-
Cardiac Troponin T (MS-295-P0) from Thermo Scientific; and Alexa Flour
488 anti-mouse (A11001) for cardiomyocytes analysis, Alexa Fluor 488
anti-mouse (A11029), Alexa Fluor 488 anti-rabbit (A11034), and Alexa
Fluor 488 anti-goat (A11055) for immunostaining of iPS clones from Life
Technologies.
RNA-Seq
Total RNAs were isolated with the RNeasy Mini Kit (QIAGEN), and cDNA
libraries of each cell were synthesized and analyzed as described before by
Fox-Walsh et al. (2011).
Cardiomyocyte Differentiation
hiPSCs were differentiated into cardiomyocytes as previously described with
minor modifications (Yang et al., 2008). Briefly, iPSCs were treated with activin
A, BMP4, bFGF, VEGF, and DKK1 in serum-free media at normoxia and video
recorded on day 15. At day 16, spontaneously contractile EBs were dissoci-
ated, replated onto glass slides, fixed in 4% formaldehyde, and immuno-
stained with mouse anti-a-actinin (Sigma-Aldrich; #A7811) or anti-Cardiac
Troponin T (Thermo Scientific; #MS-295-P0) that were detected with Anti-
Mouse IgG Alexa Fluor 488 (Life Technologies; #A11001).54, August 1, 2013 ª2013 Elsevier Inc. 253
Cell Stem Cell
Generation of iPSCs by RNA RepliconTeratoma Formation
iPSC clones were intramuscularly or subcutaneously injected into the hindlimb
muscles or dorsal flank of nude mice (approximately 10 cm dish-cultured cells
for one shot of injection). After 5–8 weeks of injection, tumors were dissected
and fixed with 4% paraformaldehyde, embedded into paraffin, and sectioned
for H&E or immunostaining.
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